BMY250502C46000
- 3.44
- 0.000.00%
Bristol-Myers Squibb Newsroom
Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $66
Piper Sandler Adjusts Bristol-Myers Squibb's Price Target to $66 From $65
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $48 From $54, Maintains Neutral Rating
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $53
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $56 From $55, Maintains Neutral Rating
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $53 From $62, Maintains Equalweight Rating
Bristol-Myers Squibb (BMY) Receives a Hold From Argus Research
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Ironwood Pharma (IRWD) and Repligen (RGEN)
Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $62
JPMorgan Cuts Price Target on Bristol-Myers Squibb to $67 From $70
TD Cowen Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $64
William Blair Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating
Research Alert: Better Than Anticipated Q1 2025 Results While Cobenfy Trial Disappoints
Bristol-Myers Squibb (BMY) Receives a Hold From TD Cowen
Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $62
Optimistic Buy Rating for Bristol-Myers Squibb Amid Low Valuation and Promising Pipeline
Citigroup Adjusts Bristol-Myers Squibb Price Target to $51 From $55
Jefferies Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $68
Bristol-Myers Squibb Analyst Ratings
Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)